Array, Loxo to develop cancer drugs in potential $434M deal

Loxo Oncology and Array BioPharma agreed to co-develop the latter's preclinical drug candidate that targets an oncogenic activating mutation. The partners also agreed to collaborate in the discovery and development of small-molecule compounds against oncology targets chosen by Loxo. The deal entitles Array to as much $434 million in milestone fees plus sales royalties.

View Full Article in:

Daily Camera (Boulder, Colo.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT